In this article, we will look at the 10 Best Strong Buy Growth Stocks to Buy Now.
On August 27, Komal Sri-Kumar, Sri-Kumar Global Strategies president, appeared on CNBC’s ‘Squawk Box’ to talk about the fallout from President Trump’s firing of Fed Governor Lisa Cook, the effects on the markets, and more.
He stated that the market reaction so far has been affected by two major reasons. Firstly, the corporate earnings numbers have been good, which has kept up the equity market.
Secondly, the markets are looking for lower short-term rates, the federal funds rate to go down, thinking that that is going to be positive for risk assets.
Sri-Kumar added that bond yields shoot up when they shoot up. When that happens, he said he wouldn’t be surprised to see a single week with a 10-year yield up 25bps or higher. He reasoned that this would happen because the yield curve would get steeper, with the 2-year yield going down and the 10-year and 30-year yields eventually going up.
READ ALSO: 13 High Growth Low PE Stocks to Invest In Now and 15 Strong Buy Stocks Under $5 to Buy Now.
He presented September to December 2024 as a historical precedent, citing one percentage point cumulative decline in the Federal funds rate between this period, while the 10-year yield increased by 90 bps during the same period.
Sri-Kumar expects it to be even worse today, stating that if the presidential firing of Lisa Cook does not survive, the markets will take over to ensure that the whole situation fails.
With these trends in view, let’s look at the best strong buy growth stocks to buy now.
Our Methodology
We used Finviz and Tipranks to make an initial list of strong buy growth stocks and selected the top 10 with consensus Strong Buy ratings and the highest number of hedge fund holders as of Q2 2025. We sourced the hedge fund sentiment data from Insider Monkey’s database, and also added the analyst upside potential for each stock. The list is sorted in ascending order of hedge fund holders.
Note: All data was sourced on August 28.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here).
10 Best Strong Buy Growth Stocks to Buy Now
10. Summit Therapeutics Inc. (NASDAQ:SMMT)
Analyst Upside: 37.07%
Number of Hedge Fund Holders: 30
Summit Therapeutics Inc. (NASDAQ:SMMT) is one of the best strong buy growth stocks to buy now. On August 27, H.C. Wainwright raised the firm’s price target on Summit Therapeutics Inc. (NASDAQ:SMMT) to $50 from $44, keeping a Buy rating on the shares.
The firm told investors in a research note that Akeso’s HARMONi-A study for ivonescimab validates the China data, showing that ivonescimab beats Keytruda.
It added that it is time to own shares of Summit Therapeutics Inc. (NASDAQ:SMMT), as it holds the position of Akeso’s partner in the United States.
Summit Therapeutics Inc. (NASDAQ:SMMT) is a biopharmaceutical company that discovers, develops, and commercializes patient, caregiver, physician, and societal-friendly medicinal therapies that target serious unmet medical needs, extend life, and enhance life quality. The company’s clinical programs focus on Clostridioides Difficile Infection (CDI).
9. Wix.com Ltd. (NASDAQ:WIX)
Analyst Upside: 46.30%
Number of Hedge Fund Holders: 42
Wix.com Ltd. (NASDAQ:WIX) is one of the best strong buy growth stocks to buy now. On August 15, Citizens JMP analyst Andrew Boone reiterated a Buy rating on Wix.com Ltd. (NASDAQ:WIX) and set a price target of $200.00.
Wix.com Ltd. (NASDAQ:WIX) reported its fiscal Q2 2025 results on August 6, with meaningful improvements in business fundamentals driving confidence in revenue growth acceleration and 2H year-over-year bookings.
The company also reported a 14% year-over-year growth in Q2 new cohort bookings. New cohorts are continuing to pick up momentum, exiting July with 20%+ year-over-year growth.
Wix.com Ltd. (NASDAQ:WIX) operates a cloud-based website design and development platform, offering a web editor, web templates, logo maker, search engine optimization, electronic mail marketing, and other services.
8. Strategy Inc. (NASDAQ:MSTR)
Analyst Upside: 70.60%
Number of Hedge Fund Holders: 45
Strategy Inc. (NASDAQ:MSTR) is one of the best strong buy growth stocks to buy now. On August 26, Canaccord Genuity analyst Joseph Vafi reiterated a Buy rating on Strategy Inc. (NASDAQ:MSTR) with a price target of $464.
The analyst considers Strategy Inc.’s (NASDAQ:MSTR) preferred stock sales as a prominent driver of shareholder value, stating that it raised over $6 billion this year through these offerings, ranking it “among the most successful in U.S. capital markets history.”
He added that while Bitcoin volatility is a considerable risk, Strategy Inc. (NASDAQ:MSTR) is still “one of the most innovative companies” under his coverage. Vafi expects more firms to adopt its Bitcoin-driven treasury strategy.
7. Exact Sciences Corporation (NASDAQ:EXAS)
Analyst Upside: 35.79%
Number of Hedge Fund Holders: 50
Exact Sciences Corporation (NASDAQ:EXAS) is one of the best strong buy growth stocks to buy now. On August 21, Jefferies analyst Tycho Peterson reiterated a Buy rating on Exact Sciences Corporation (NASDAQ:EXAS) and set a price target of $80.00.
Exact Sciences Corporation (NASDAQ:EXAS) reported its fiscal Q2 2025 earnings on August 6, announcing a record total revenue of $811 million for the quarter, up 16% on a reported and core revenue basis.
The company raised its full-year 2025 revenue and adjusted EBITDA guidance midpoints by $55 million and $25 million, respectively, and also announced a multi-year productivity plan targeting $150 million in annual savings by 2026.
Exact Sciences Corporation (NASDAQ:EXAS) is a diagnostics and screening company that focuses on the early detection and prevention of particular types of cancer. It offers Cologuard, a non-invasive screening test for the early detection of colorectal cancer, pre-cancer, and Oncotype DX.
6. Hubspot, Inc. (NYSE:HUBS)
Analyst Upside: 42.27%
Number of Hedge Fund Holders: 56
Hubspot, Inc. (NYSE:HUBS) is one of the best strong buy growth stocks to buy now. In a report released on August 28, J. Parker Lane from Stifel Nicolaus maintained a Buy rating on Hubspot, Inc. (NYSE:HUBS), setting a price target of $650.00.
The rating came after Hubspot, Inc. (NYSE:HUBS) reported its fiscal Q2 2025 earnings on August 6, with total revenue for the quarter reaching $760.9 million, up 19% on an as-reported basis and 18% in constant currency compared to the same quarter last year.
Subscription revenue rose 19% on an as-reported basis to $744.5 million, while Professional services and other revenue grew 21% on an as-reported basis to $16.3 million.
HubSpot (NYSE:HUBS also reported a GAAP operating margin of 3.2%, compared to 3.8% in fiscal Q2 2024.
HubSpot (NYSE:HUBS) is an American developer and marketer of software products for inbound marketing, customer service, and sales.
Its unified platform offers prime connection for customer-facing teams, and includes artificial intelligence-powered engagement hubs, a connected ecosystem with more than 1,500 app marketplace integrations, a smart customer relationship management product (CRM), a community network, and educational content.
The company’s engagement hubs include Sales Hub, Marketing Hub, Operations Hub, Service Hub, Content Management System Hub, and Commerce Hub. These hubs allow companies to engage and attract clients through the customer lifecycle.
5. Teva Pharmaceutical Industries Limited (NYSE:TEVA)
Analyst Upside: 33.85%
Number of Hedge Fund Holders: 57
Teva Pharmaceutical Industries Limited (NYSE:TEVA) is one of the best strong buy growth stocks to buy now. On August 28, Teva Pharmaceutical Industries Limited (NYSE:TEVA) announced the FDA approval and U.S. launch of Generic Saxenda, the first-ever generic GLP-1 indicated for weight loss, targeting the rising demand for this category of therapies in the US market.
Management reported that the Liraglutide injection is indicated for “adults with obesity or overweight (excess weight) who also have weight-related medical problems, and pediatric patients (12-17 years) with a weight greater than 60 kg and obesity to help them lose weight and keep the weight off.”
Ernie Richardsen, SVP, Head of U.S. Commercial Generics at Teva Pharmaceutical Industries Limited (NYSE:TEVA), stated that this marks “the fifth first-to-market entry of a Teva generic this year and is an important addition to Teva’s diverse complex generics portfolio, demonstrating once again our proven ability to sustain a world-class Generics Powerhouse.”
Teva Pharmaceutical Industries Limited (NYSE:TEVA) develops, produces, and sells medicines. Its operations are divided into the US, Europe, and International Markets geographical segments. Each business segment covers the entire product portfolio in that region, including specialty, generics, and over-the-counter (OTC) products.
4. Nutanix, Inc. (NASDAQ:NTNX)
Analyst Upside: 41.52%
Number of Hedge Fund Holders: 58
Nutanix, Inc. (NASDAQ:NTNX) is one of the best strong buy growth stocks to buy now. On August 28, BofA analyst Wamsi Mohan lowered the firm’s price target on Nutanix, Inc. (NASDAQ:NTNX) to $93 from $95, keeping a Buy rating on the shares.
The analyst told investors in a research note that Nutanix, Inc.’s (NASDAQ:NTNX) fiscal Q4 results came above expectations, with the initial view for fiscal year 2026 likely to be conservative, primarily because management has historically guided conservatively in delivering the first guidance for a year.
Mohan added that Nutanix, Inc. (NASDAQ:NTNX) has surpassed operating margin guidance by 500 basis points, on average, over the past three years.
Nutanix, Inc. (NASDAQ:NTNX) provides a cloud platform leveraging web-scale engineering and consumer-grade design. The company’s operations are divided into the following geographic segments: the United States, Europe, the Middle East, Africa, Asia Pacific, and Other Americas.
3. BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)
Analyst Upside: 69.93%
Number of Hedge Fund Holders: 58
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is one of the best strong buy growth stocks to buy now. On August 19, Bernstein analyst William Pickering maintained a Buy rating on BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) and set a price target of $95.00.
Similarly, Evercore ISI analyst Cory Kasimov also maintained a Buy rating on BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) on August 11, setting a price target of $110.00.
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) has an analyst consensus of Strong Buy, with its median price target of $57.48 implying an upside of 70.49% from current levels.
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) develops and commercializes therapies for serious and life-threatening medical conditions and rare diseases. The company’s product pipeline includes Valoctocogene roxaparvovec, Vosoritide, and BMN 307.
2. DexCom, Inc. (NASDAQ:DXCM)
Analyst Upside: 36.64%
Number of Hedge Fund Holders: 60
DexCom, Inc. (NASDAQ:DXCM) is one of the best strong buy growth stocks to buy now. On August 21, Argus initiated coverage of DexCom, Inc. (NASDAQ:DXCM) with a Buy rating and $100 price target.
The firm told investors in a research note that it sees DexCom, Inc. (NASDAQ:DXCM) maintaining above industry average growth, leveraging costs to boost profitability, and expanding its customer reach across the continuous glucose monitoring for diabetes landscape.
It added that DexCom, Inc. (NASDAQ:DXCM) has “robust” free cash flows that bolster its balance sheet and allow higher-than-peer research and development investments that drive product innovation.
The firm views the current share levels as an attractive entry point for DexCom, Inc. (NASDAQ: DXCM).
DexCom, Inc. (NASDAQ:DXCM) is a medical device company that manufactures continuous glucose monitoring (CGM) systems to allow real-time health management control. Specializing in diabetes care technology, the company helps improve and simplify diabetes management worldwide.
It offers various medical devices and products, including Dexcom G6, Dexcom G7, Dexcom Stelo, Dexcom Share, Dexcom Real-Time API, and Dexcom ONE.
1. monday.com Ltd. (NASDAQ:MNDY)
Analyst Upside: 45.17%
Number of Hedge Fund Holders: 67
monday.com Ltd. (NASDAQ:MNDY) is one of the best strong buy growth stocks to buy now. On August 21, Wells Fargo analyst Michael Berg maintained a Hold rating on monday.com Ltd. (NASDAQ:MNDY) without assigning a price target.
Monday.com Ltd. (NASDAQ:MNDY) reported its fiscal Q2 2025 results on August 11, with revenue for the quarter rising 27% year-over-year to $299.0 million.
The company added a record number of net new customers with over $100k in ARR, with Monday CRM recently reaching $100 million in ARR.
Monday.com Ltd. (NASDAQ:MNDY) operates a cloud-based visual work operating system that comprises modular building blocks that can be easily assembled and used for the creation of work management tools and software applications, acting as a connective layer to integrate with an organization’s various digital tools.
The company’s operations are divided into the following geographical segments: United States, EMEA, United Kingdom, and Rest of the World.
While we acknowledge the potential of MNDY to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than MNDY and that has 100x upside potential, check out our report about this cheapest AI stock.
READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.
Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.
